Also an antibody targeting PD-1, pembrolizumab has been assessed for its safety and antitumor activity in KEYNOTE-028 phase Ib trial treating patients with PD-L1+unresectable or metastatic NPC [386]. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.